Literature DB >> 23802844

Outcome of pediatric acquired aplastic anemia: a developing world experience.

Mohammed Ramzan1, S P Yadav, Mir Sadaqat Hassan Zafar, Veronique Dinand, Anupam Sachdeva.   

Abstract

INTRODUCTION: Outcome data of children with acquired aplastic anemia (AA) are lacking from the developing world. Here, we describe the same from a centre in North India.
METHODS: Retrospective data regarding medical history, physical examination, complete blood count, bone marrow aspirate, and biopsy were retrieved for all children <18 years, with acquired AA admitted between January 2005 and June 2012. In addition, the outcome data after immunosuppressive therapy (IST) or bone marrow transplant (BMT) was obtained.
RESULTS: A total of 61 children were diagnosed with AA (Inherited-18 and acquired-43). Among 43 children with acquired AA, 3 had nonsevere and 40 had severe. One patient with nonsevere AA died of sepsis and 2 recovered spontaneously. Of the 40 remaining children with severe AA, 10 refused therapy and 3 died due to severe sepsis prior to any therapy. Five underwent upfront matched sibling donor BMT and one post-IST failure. Four year overall survival (OS) and event free survival (EFS) for children undergoing BMT was 100% and 80 ± 17.9, respectively. Out of 22 treated with IST, 20 were evaluable for response. Seventeen received one course and 3 received two course of IST. The overall response to IST was seen in 14/20 (70%). Only two achieved complete response while remaining 12 had partial response. The 4-year estimated OS and EFS for children treated with IST was 74.4 ± 12.1% and 65.6 ± 12.2.
CONCLUSION: Outcomes for children with AA are encouraging in the developing world although barriers like sepsis and treatment abandonment remain. BMT offers faster and complete recovery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23802844     DOI: 10.3109/08880018.2013.807898

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Response to Horse ATG (Thymogam, Bharat Serums and Vaccine, India) and Cyclosporine in Aplastic Anemia: A Single Centre, Retrospective Study of 60 Patients from Southern India.

Authors:  Deepak S Amalnath
Journal:  Indian J Hematol Blood Transfus       Date:  2019-05-20       Impact factor: 0.900

2.  Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study.

Authors:  Xiao-Fan Zhu; Hai-Long He; Shun-Qing Wang; Jing-Yan Tang; Bing Han; Dong-Hua Zhang; Li-Qiang Wu; De-Pei Wu; Wei Li; Ling-Hui Xia; Huan-Ling Zhu; Feng Liu; Hong-Xia Shi; Xi Zhang; Fang Zhou; Jian-Da Hu; Jian-Pei Fang; Xie-Qun Chen; Tie-Zhen Ye; Ying-Min Liang; Jie Jin; Feng-Kui Zhang
Journal:  Acta Haematol       Date:  2019-05-15       Impact factor: 2.195

Review 3.  Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT).

Authors:  Raheel Iftikhar; Parvez Ahmad; Regis de Latour; Carlo Dufour; Antonio Risitano; Naeem Chaudhri; Ali Bazarbachi; Josu De La Fuente; Britta Höchsmann; Syed Osman Ahmed; Usama Gergis; Alaa Elhaddad; Constantijn Halkes; Bassim Albeirouti; Sultan Alotaibi; Austin Kulasekararaj; Hazzaa Alzahrani; Tarek Ben Othman; Simone Cesaro; Ali Alahmari; Rawad Rihani; Salem Alshemmari; Amir Ali Hamidieh; Mohamed-Amine Bekadja; Jakob Passweg; Murtadha Al-Khabori; Walid Rasheed; Andrea Bacigalupo; Qamar-Un-Nisa Chaudhry; Per Ljungman; Judith Marsh; Riad El Fakih; Mahmoud Aljurf
Journal:  Bone Marrow Transplant       Date:  2021-05-19       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.